Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NeoTX Therapeutics Ltd.
Dana-Farber Cancer Institute
NGM Biopharmaceuticals, Inc
Pfizer
NGM Biopharmaceuticals, Inc
Quadriga Biosciences, Inc.
Xencor, Inc.
MacroGenics
Abramson Cancer Center at Penn Medicine
Fox Chase Cancer Center
Kantonsspital Winterthur KSW
Masonic Cancer Center, University of Minnesota
Valerio Therapeutics
INSYS Therapeutics Inc
University of Chicago
National Cancer Institute (NCI)
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)